Gilead Sciences | GILD - Des Atouts





Des Atouts Changement Date
AbbVie USD 136.46B 2.5B 2026-03
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
ALKERMES USD 4.26B 1.77B 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Amgen USD 92.5B 1.92B 2026-03
Biogen USD 29.48B 43.6M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Coherus Biosciences USD 258.34M 258.18M 2025-12
Eli Lilly USD 116.58B 4.1B 2026-03
Gilead Sciences USD 56.28B 2.74B 2026-03
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
Glaxosmithkline GBP 82.34B 102.25M 2025-12
Incyte USD 7.34B 381.14M 2026-03
J&J USD 200.89B 1.68B 2026-03
Merck USD 128.68B 8.18B 2026-03
Moderna USD 11.49B 850M 2026-03
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Novartis USD 118.53B 7.58B 2026-03
Pfizer USD 207.62B 542M 2026-03
PTC Therapeutics USD 2.87B 29.66M 2026-03
Puma Biotechnology USD 202.86M 7.95M 2025-09
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sanofi EUR 128.02B 1.22B 2026-03
Sarepta Therapeutics USD 3.18B 170.77M 2026-03
United Therapeutics USD 6.71B 1.17B 2026-03
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03